Ziltivekimab
Ziltivekimab Basic information
- Product Name:
- Ziltivekimab
- Synonyms:
-
- Ziltivekimab
- Research Grade Ziltivekimab(DHC15802)
- Research Grade Ziltivekimab
- Ziltivekimab (anti-IL-6)
- CAS:
- 2226654-05-1
- MW:
- 0
- Mol File:
- Mol File
Ziltivekimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Ziltivekimab Usage And Synthesis
Uses
Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis[1][2].
in vivo
Ziltivekimab (s.c., once every 4 weeks for a total of 24 weeks) can significantly reduce various biomarkers involved in stimulating the process of atherosclerosis and thrombosis (such as hsCRP (high-sensitivity C-reactive protein), fibrinogen, serum amyloid A, apolipoprotein A, secretory phospholipase A2, and lipoprotein (a)), which are also associated with systemic inflammation[4].
IC 50
IL-6
References
[1] Kristen L Nowak, et al. A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360. 2020 Dec 4;2(2):224-235. DOI:10.34067/KID.0005862020
[2] Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117(11):e138-e140. DOI:10.1093/cvr/cvab231
[3] Gluba-Brzózka A, et al. Emerging Anti-Atherosclerotic Therapies. Int J Mol Sci. 2021 Nov 9;22(22):12109. DOI:10.3390/ijms222212109
ZiltivekimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com